Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Airlines

Delta Air Lines

SPDR S&P 500 ETF Trust

United Continental Hlds

It's the third-straight day in the red for the Dow, S&P 500 and Nasdaq, which fell 0.07%, 0.15% and 0.47%, respectively.

Headwinds Persist, Major Markets Down 3rd Straight Day: DAL, AAL, UAL, WBA

Walgreens Boots Alliance, Inc. (WBA) CEO Stefano Pessina on Q4 2020 Results - Earnings Call Transcript

Walgreens Boots Alliance (NASDAQ: WBA) said on Thursday that its profit in the fiscal fourth quarter contracted less than expected. Revenue in Q4, it added, came in stronger than what the analysts had anticipated.

Walgreens Boots Alliance’s sales come in 2.3% higher in fiscal Q4

Earnings season has kicked off and investors are already chasing the winners higher and punishing the losers.

Actually, Walgreens Did Prove Its Relevance on Earnings

Earlier this month, I wrote that I felt Walgreens Boots Alliance (NASDAQ:WBA) was a dividend growth investor's dream stock. I continue to believe this to be true because the company rates highly in terms of profitability, capital returns, dividend yield and track record.

Walgreens' 4th Quarter Shows Positive Signs

The stock market is waking up to the potential for a rough winter ahead, and there's no economic stimulus in sight.

Dow Jones Tumbles 250 Points on Coronavirus Fears; Walgreens Beats on Revenue and Earnings; IBM Announces Cloud Deals

Walgreens Boots' (WBA) fiscal fourth-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.

Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Down

Walgreens Boots Alliance reported a $520 million “adverse Covid-19 impact” in its fourth quarter as the global drugstore chain begins a slow rebound during the pandemic.

Walgreens Sees Store Rebound Despite $520 Million Covid-19 Hit

Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported fiscal fourth-quarter and full-year 2020 results before markets opened Thursday.

There’s Plenty for Investors to Like About Walgreens

Walgreens (WBA) delivered earnings and revenue surprises of 6.25% and 1.08%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Beats Q4 Earnings and Revenue Estimates

Shares of Walgreens Boots Alliance Inc. jumped 2.8% in premarket trading Thursday, after the drug-store services company reported a fiscal fourth-quarter profit that fell less than expected, while revenue rose above forecasts. Net income fell to $373 million, or 43 cents a share, from $677 million, or 75 cents a share, in the year-ago period.

Walgreens stock jumps after profit falls less than expected, revenue rises above forecasts

Drugstore chain Walgreens Boots Alliance Inc said on Thursday its quarterly profit slumped 44.9%, as COVID-19 hampered sales at its retail stores in the United States and at its Boots UK unit.

Walgreens fourth-quarter profit slumps 44.9% as COVID-19 hits store sales

Shares of Walgreens Boots Alliance (NASDAQ:WBA) rose 3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 28.67% year over year to $1.02, which beat the estimate of $0.96.

Walgreens Boots Alliance: Q4 Earnings Insights

DEERFIELD, Ill.--(BUSINESS WIRE)---- $wba #earnings--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) announced financial earnings for the fiscal year and fourth quarter that ended August 31, 2020.

Walgreens Boots Alliance Reports Fiscal Year 2020 Results

Intuitive Surgical

Kansas City Southern

Schlumberger

V.F.

There are more than just banks reporting this first week of earnings season.

5 Important Earnings Chart to Watch This Week

Walgreens, the second-largest pharmacy chain in the U.S., is set to report earnings before the bell Thursday. Here's what to expect after the release.

Ahead of Walgreens earnings, two market analysts share whether it’s a buy

Cisco Systems

People's United Financial

AT&T

With the strong dividend metrics in hand, we purchased Cisco on multiple occasions this month.

Dividend Stock Purchases: Bert's September 2020 Summary

Marriott

They've weighed on the market all year. Some see them finally catching up.

Are These Nasdaq Laggards Ready to Explode Higher?

Walgreens Boots Alliance (WBA) hasn't gained any sustained momentum during the market comeback, with the stock down 37% in 2020, against the S&P 500's 8% jump.

Evaluating Struggling Walgreens (WBA) Stock Ahead of Q4 Earnings

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA Co-COO Ornella Barra highly commended for her sustainability leadership at the Responsible Business Awards 2020.

Walgreens Boots Alliance Co-COO Ornella Barra Highly Commended for Responsible Business Leadership

Apple

Alibaba

Canopy Growth

Cigna

Eli Lilly

UnitedHealth Group

Investors have these seven election stocks to consider avoiding, as uncertainties grow in the near-term and market selling rises. The post 7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote appeared first on InvestorPlace.

7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote

Walgreens' (WBA) retail pharmacy international sales remain dull in Q4 on difficult market scenario in the U.K.

Will Walgreens (WBA) Post Dull Retail Numbers in Q4 Earnings?

Johnson & Johnson

Bank of America

Citigroup

Goldman Sachs

JPMorgan Chase & Co

Wells Fargo

A new earnings reporting season kicks off this week, with the big banks and a few other companies leading the way.

Citigroup, Goldman Sachs, Johnson & Johnson, Walgreens and More Major Earnings This Week

Altria

Teva Pharmaceutical

These brand-name value stocks are now ripe for the picking.

5 Turnaround Stocks That Are Screaming Buys

AbbVie

Franklin Resources

Cardinal Health

Chevron

Federal Realty Investment Trust

Realty Income Corp

Exxon Mobil

"S&P 500 Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years." - us.spindices.com.

News for Walgreens Stock (WBA)